



23 May 2022

EKF Diagnostics Holdings plc
("EKF", the "Company" or the "Group")

Cancellation of Treasury Shares and TVR

EKF Diagnostics Holdings plc (AIM: EKF), the AIM-listed global diagnostics business, refers to its announcement dated 11 April 2022, surrounding the completion of the Company's buyback programme of 9,000,000 shares, currently held in Treasury. The Company confirms these shares will be cancelled with effect from 24 May 2022 (the "Cancellation").

Following the Cancellation, the Company's total issued share capital will consist of 454,930,564 ordinary shares of 1 pence each ("Ordinary Shares") with one voting right per share. The Company will not hold any Ordinary Shares in treasury.

Therefore, the total number of voting rights in the Company will be of 454,930,564.

The above figure of 454,930,564 may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure and Transparency Rules.

EKF Diagnostics Holdings plc

Mike Salter, CEO
Marc Davies, CFO

www.ekfdiagnostics.com

Tel: +44 (0)29 2071 0570

Singer Capital Markets (Nominated Adviser & Joint Broker)

Aubrey Powell / George Tzimas

Tel: +44 (0)20 7496 3000

Investec Bank plc (Joint Broker)

Gary Clarence / Daniel Adams / Ben Farrow

Tel: +44 (0)20 7597 4000

Walbrook PR Limited

Paul McManus / Lianne Applegarth

Tel: +44 (0)20 7933 8780 or ekf@walbrookpr.com

Mob: +44 (0)7980 541 893 / +44 (0)7584 391 303

About EKF Diagnostics Holdings plc (www.ekfdiagnostics.com)

EKF is a leading global diagnostics business with custom manufacturing facilities across sites in the US, UK and Europe for a variety of life science products. EKF is focussed on the following areas:

Point-of-Care

Providing a portfolio of Point-of-Care analysers and consumables, particularly for use in the area of Hematology and Diabetes, for use in hospital and research laboratories, doctor's offices, blood banks and for in-field anaemia screening programmes. EKF has an estimated 80,000 hemoglobin, hematocrit, HbA1c, glucose and lactate analysers in regular use across more than 100 countries.

Central Laboratory

Clinical chemistry, Small lab analysers, Centrifuges
Beta-Hydroxybutyrate (β -HB) LiquiColor, Glycates Albumin, Glycated Serum Protein, Nitro-tab, Procalcitonin

Life Sciences

Enzyme fermentation, Custom products and Bulk fermentation

Contract Manufacturing Bulk formulation, Sample collection kits, Private labelling, Molecular and forensic kits

Laboratory Services In September 2021, EKF completed the acquisition of Advanced Diagnostic Laboratory LLC ("ADL Health"), a Texas based testing laboratory certified under the Clinical Laboratory Improvement Amendments ("CLIA") for high complexity testing. The laboratory provides testing for a variety of clinical, forensic and microbiological sample types using a range of analytical techniques. This acquisition positions EKF as a leading 'one stop' provider of diagnostic products and services from sample collection to results.

EKF's growth strategy to 2024 and beyond can be summarised as:

- continuing innovation in products and services in Point-of-Care, Central Laboratory and Life Sciences leveraging new and existing routes to market and relationships;
- investment in expanded production and kitting capabilities to offer a suite of diagnostic Contract Manufacturing solutions to third party businesses;
- expansion of CLIA Laboratories Testing offering, building on the acquired capabilities in ADL Health; and
- identify complementary earnings-enhancing acquisitions with key strategic value.

EKF will also continue to generate enhanced shareholder value through:

- a progressive dividend policy; and
- its agreement with Mount Sinai Innovation Partners ("MSIP"), which allows us advanced access to innovative commercial opportunities and where we can build on the ongoing successes of Renalytix plc, Verici Dx plc and Trellus Health plc.